Themis Medicare Limited (THEMISMED) AI Stock Analysis

• Market Cap: ₹12.13B
• Dividend Yield: 0.38%
• Average Volume (3M): 30.46K
• Price to Earnings (P/E): 33.1
• Beta (1Y): 1.98
• Revenue Growth: -6.86%
• EPS Growth: -118.14%
• Country: IN
• Employees: 1,509
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.54
• Shares Outstanding: 92,040,120
• 10 Day Avg. Volume: 71,251
• 30 Day Avg. Volume: 30,457
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹142.00
• Price Target Upside: 7.71% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹142.00 ▲(7.71% Upside)

Themis Medicare Limited's overall stock score is driven by strong financial performance and positive technical indicators. However, the negative P/E ratio and low dividend yield present significant valuation concerns, impacting the overall attractiveness of the stock.

Themis Medicare Limited Business Overview & Revenue Model

Company Description

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was incorporated in 1969 and is headquartered in Mumbai, India.

How the Company Makes Money

Themis Medicare Limited generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around manufacturing and marketing its proprietary medicines across domestic and international markets. Key revenue streams include sales to healthcare providers, hospitals, and pharmacies. The company may also engage in partnerships and collaborations with other pharmaceutical entities to co-develop or distribute products, enhancing its market reach and profitability. Additionally, Themis Medicare invests in research and development to innovate and introduce new products, which can contribute to future revenue growth.

Themis Medicare Limited Financial Statement Overview

Summary

Themis Medicare Limited exhibits robust growth and operational efficiency with strong revenue and gross profit metrics. The balance sheet shows a stable financial footing with managed leverage and solid equity. Cash flow statements indicate effective cash management, although there is room for improvement in aligning free cash flow with net income.

Income Statement

Themis Medicare Limited demonstrates strong revenue growth with a consistent increase in total revenue over the years, highlighted by a significant jump from 2020 to 2025. The company has maintained high gross profit margins, indicating efficient cost management. However, net profit margin has been volatile, with a noticeable decline in the recent period, suggesting potential challenges in managing expenses or increased competition affecting profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a healthy equity ratio and improving return on equity. The debt-to-equity ratio is managed well, indicating balanced leverage, though there is a slight increase in total debt in recent periods. Overall, the company's financial structure supports its growth but could benefit from further equity strengthening.

Cash Flow

Cash flows show a positive trajectory with improving operating cash flows and a strong free cash flow recovery after negative figures in earlier years. However, the free cash flow to net income ratio highlights some inconsistencies, suggesting areas for improvement in cash generation relative to profits. The company has been able to manage capital expenditures effectively to enhance free cash flow.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.06B	4.06B	3.82B	3.95B	3.54B	2.31B
Gross Profit	2.23B	2.74B	2.42B	2.43B	2.36B	1.50B
EBITDA	490.48M	490.48M	733.17M	1.02B	789.56M	531.16M
Net Income	298.33M	298.33M	435.24M	728.81M	569.01M	357.03M
Balance Sheet
Total Assets	5.88B	5.88B	5.66B	4.28B	5.14B	3.71B
Cash, Cash Equivalents and Short-Term Investments	128.37M	128.37M	99.22M	202.79M	238.09M	190.18M
Total Debt	829.88M	829.88M	957.92M	797.32M	923.75M	871.82M
Total Liabilities	1.85B	1.85B	1.89B	1.40B	1.75B	1.53B
Stockholders Equity	4.03B	4.03B	3.78B	2.87B	3.39B	2.19B
Cash Flow
Free Cash Flow	0.00	192.84M	36.76M	137.67M	-126.55M	389.36M
Operating Cash Flow	0.00	347.10M	220.94M	343.94M	160.93M	569.75M
Investing Cash Flow	0.00	-121.74M	-159.48M	-155.86M	-239.62M	-156.51M
Financing Cash Flow	0.00	-258.98M	-87.70M	-175.47M	1.36M	-256.47M

Themis Medicare Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 131.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THEMISMED, the sentiment is Positive. The current price of 131.84 is above the 20-day moving average (MA) of 117.80, above the 50-day MA of 112.59, and below the 200-day MA of 160.91, indicating a neutral trend. The MACD of 8.08 indicates Negative momentum. The RSI at 60.97 is Neutral, neither overbought nor oversold. The STOCH value of 71.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THEMISMED.

Themis Medicare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAGSNPHARM	69 Neutral	₹14.29B	23.40	23.07%	1.17%	34.72%	196.94%
THEMISMED	65 Neutral	₹12.13B	33.15	―	0.38%	-6.86%	-118.14%
KOPRAN	65 Neutral	₹8.38B	23.99	7.44%	1.73%	-1.83%	-41.16%
BLISSGVS	63 Neutral	₹15.32B	14.33	8.03%	0.34%	4.93%	29.92%
WANBURY	62 Neutral	₹8.13B	18.87	51.51%	―	12.37%	-17.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Themis Medicare Limited Corporate Events

Themis Medicare Limited Announces 55th AGM

Themis Medicare Limited has announced the convening of its 55th Annual General Meeting (AGM) scheduled for September 12, 2025. The meeting will be held to discuss both ordinary and special business matters as outlined in the AGM notice. This announcement is part of the company’s compliance with SEBI Listing Regulations, reflecting its commitment to transparency and stakeholder engagement.

Themis Medicare Announces Key Leadership Appointments and Financial Updates

Themis Medicare Limited announced significant changes in its leadership team, including the appointment of Ms. Neha Thakore as an Additional Non-Executive Woman Independent Director and Mr. Viraj Save as Executive President of Sales & Marketing. These appointments are expected to strengthen the company’s strategic direction and operational capabilities. Additionally, the company approved its un-audited financial results for the quarter ended June 30, 2025, and set a record date for determining the entitlement of members to receive the final dividend for the financial year ended March 31, 2025.

Themis Medicare Strengthens Leadership with Key Appointments

Themis Medicare Limited announced the appointment of Ms. Neha Thakore as an Independent Director and Mr. Viraj Save as Executive President of Sales & Marketing, effective August 1, 2025. These appointments are part of the company’s strategic efforts to strengthen its leadership team and enhance its market position. Additionally, the company approved its unaudited financial results for the quarter ending June 30, 2025, and set a record date for determining dividend entitlements, indicating a focus on financial transparency and shareholder value.